Salt and solid forms of a kinase inhibitor
AssigneeBlueprint Medicines Corporation
InventorsErika Butler, Nimita Dave, Tuan Dong Si, Brian Heinrich, Caitlin N. Kinkema, Christopher Lee, Hui Li, Lauren MacEachern, Clare Aubrey Medendorp
Life of this patent
Estimating the term…
Abstract
Various salt forms and free base solid forms of Compound (I) represented by the following formula are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making the salt forms of Compound (I) and crystalline forms thereof are also disclosed.
Claims35
A phosphate salt, a besylate salt, a sulfate salt, or a benzoate salt of Compound (I) represented by the following Formula:
- wherein the molar ratio between Compound (I) and phosphoric acid is 1:1, the molar ratio between Compound (I) and benzene sulfonic acid is 2:1, the molar ratio between Compound (I) and sulfuric acid is 1:1, and the molar ratio between Compound (I) and benzoic acid is 1:1
(canceled)
6-10. (canceled)
12-16. (canceled)
18-22. (canceled)
24-26. (canceled)
28-30. (canceled)
32-35. (canceled)
(canceled)
39-44. (canceled)
(canceled)
48-53. (canceled)
55-57. (canceled)
An amorphous form of Compound (I) represented by the following Formula:
(canceled)
A method of treating indolent systemic mastocytosis (ISM) or monoclonal mast cell activation syndrome (mMCAS) comprising orally administering to a patient in need thereof an amount of 15 mg to 200 mg of Compound (I)
- or a pharmaceutically acceptable salt thereof in an amount equivalent to 15 mg to 200 mg of Compound (I), once a day.
64-65. (canceled)
(canceled)
Dependencies are inferred from the claim text.